{"links":{"feed":"https://www.erudio.com/reports/rmc-6236-001-nct05379985/feed.json","html":"https://www.erudio.com/reports/rmc-6236-001-nct05379985","json":"https://www.erudio.com/reports/rmc-6236-001-nct05379985.json","markdown":"https://www.erudio.com/reports/rmc-6236-001-nct05379985.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rmc-6236-001-05379985"}},"request":"https://www.erudio.com/contact?report=rmc-6236-001-05379985"},"offer":{"cited_clinicians":19,"cited_commentary_sources":49,"verified_hcp_statements":196,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization; never for outreach to or targeting of clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":29,"optional":true,"price_per_verified_person_usd":15,"price_usd":435,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rmc-6236-001-nct05379985"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rmc-6236-001-05379985","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rmc-6236-001-nct05379985","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 196 verified statements · 47 from 19 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need at least 5 confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); with fewer, a report is sold one size down.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-04T16:40:09.546797Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":1},"aspects":[{"claim_count":15,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":10,"title":"Primary endpoint: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Number of Participants with Dose-Limiting Toxicity (DLT)"},{"claim_count":24,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":19,"title":"Secondary endpoints"},{"claim_count":18,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":23,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":7,"title":"Dose optimization and the efficacy–tolerability trade-off"},{"claim_count":15,"coverage":"discussed","id":"A2","source_count":10,"title":"Broader RAS coverage, biological relevance and platform interpretations"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":6,"title":"ctDNA, resistance, prior RAS-inhibitor sequencing and CNS questions"},{"claim_count":14,"coverage":"discussed","id":"A4","source_count":8,"title":"First-line PDAC monotherapy and distinct combination strategies"},{"claim_count":15,"coverage":"discussed","id":"A5","source_count":10,"title":"Access, eligibility, patient support and indication-specific communication"},{"claim_count":29,"coverage":"discussed","id":"A6","source_count":14,"title":"Historical benchmarks, randomized corroboration and thresholds for practice change"}],"counts":{"cited_clinicians":19,"cited_clinicians_by_role":{"physician":2,"physician, Cardiology":1,"physician, Medical oncology":15,"physician, Pathology":1},"cited_physicians":19,"cited_sources":50,"claims_by_expression_type":{"comparison":16,"experience":2,"interpretation":69,"opinion":35,"primary_context":8,"question":13,"restatement":17,"uncertainty":7,"unspecified":29},"claims_by_kind":{"interpretation":4,"publication_statement":16,"source_observation":176},"clinician_statements":47,"evidence_units":189,"findings":9,"organisational_accounts":11,"people_cited":34,"people_identity_verified":29,"people_total":34,"screened_sources":87,"verified_claims":196},"findings_index":[{"id":"F1","structure":{"claims":23,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":6,"views":12},"limitations":4,"links":{"context":1,"support":25},"ma_question":true,"named_voices":5,"passages":23,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"Speakers welcome NSCLC activity beyond G12C; one discussion challenges the highlighted 42% response estimate"},{"id":"F2","structure":{"claims":30,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":8,"views":18},"limitations":4,"links":{"context":2,"support":32},"ma_question":true,"named_voices":6,"passages":31,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Speakers favor a lower NSCLC dose on tolerability grounds and stress the burden of toxicity"},{"id":"F3","structure":{"claims":36,"claims_by_group":{"comparisons":4,"experience":0,"questions":4,"restated":7,"views":21},"limitations":4,"links":{"context":0,"support":40},"ma_question":true,"named_voices":20,"passages":27,"sources":16,"sources_by_kind":{"commentary":15,"media":1}},"title":"Speakers differ on whether previously treated PDAC activity is enough to change practice"},{"id":"F4","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":10},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":8,"passages":11,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Speakers describe manageable PDAC toxicity as work-intensive; one clinician asks whether skin toxicity is unfamiliar"},{"id":"F5","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":2,"views":12},"limitations":4,"links":{"context":0,"support":26},"ma_question":true,"named_voices":9,"passages":21,"sources":11,"sources_by_kind":{"commentary":8,"media":2,"publication":1}},"title":"Speakers see a conceptual advance and discuss a possible RAS-treatment platform"},{"id":"F6","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":11},"limitations":4,"links":{"context":0,"support":16},"ma_question":true,"named_voices":5,"passages":15,"sources":7,"sources_by_kind":{"commentary":4,"media":2,"publication":1}},"title":"Speakers flag resistance and sequencing gaps; one also highlights CNS activity"},{"id":"F7","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":1,"questions":3,"restated":2,"views":8},"limitations":5,"links":{"context":2,"support":17},"ma_question":true,"named_voices":9,"passages":15,"sources":9,"sources_by_kind":{"commentary":8,"publication":1}},"title":"Speakers welcome first-line PDAC monotherapy, while combination views range from enthusiasm to doubt"},{"id":"F8","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":5,"views":7},"limitations":5,"links":{"context":0,"support":21},"ma_question":true,"named_voices":6,"passages":16,"sources":10,"sources_by_kind":{"commentary":7,"media":3}},"title":"One clinician asks about off-label NSCLC access; other sources stress route-specific restrictions"},{"id":"F_context_without_trial_name","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"How do account-authored assessments frame daraxonrasib activity and severe adverse events in NSCLC and PDAC?"}],"medical_affairs_question":"How can Medical Affairs preserve cohort-specific benefit estimates, the practical burden of toxicity and the distinction between evidence and access in the same conversation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers welcome NSCLC activity beyond G12C; one discussion challenges the highlighted 42% response estimate"},{"id":"section-2","level":2,"title":"How do speakers weigh NSCLC dose, toxicity attribution and treatment persistence?"},{"id":"section-3","level":2,"title":"Is the PDAC signal sufficient to change practice?"},{"id":"section-4","level":2,"title":"How should PDAC skin and gastrointestinal toxicity be managed?"},{"id":"section-5","level":2,"title":"What do speakers mean by a broader RAS-treatment platform?"},{"id":"section-6","level":2,"title":"What remains unknown about resistance, prior RAS therapy and CNS activity?"},{"id":"section-7","level":2,"title":"How do speakers distinguish first-line PDAC monotherapy from combination strategies?"},{"id":"section-8","level":2,"title":"What access routes are speakers considering, and under which restrictions?"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":11},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F_context_without_trial_name","shared_claims":1}],"id":"T1","label":"Primary endpoint: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs"},{"findings":[],"id":"T2","label":"Primary endpoint: Number of Participants with Dose-Limiting Toxicity (DLT)"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":12},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2},{"id":"F_context_without_trial_name","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":6},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6},{"id":"F7","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":10},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":12},{"id":"F5","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":3}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-04T16:40:09.546797Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-04T16:58:25Z","record_hash":"c4892cfe9d7339c0afeae4f72dcf2c917f79ea9b640abc2c35d04842584c5b88","release_hash":"5c02680ee9bf243915ef2f4967faf69e67ae10262364ae4e56abe96a4102016b","report_id":"erudio-nct05379985","run_id":"e8d45364-6a2f-47de-8f77-08c619b11107","schema_version":"5.0","slug":"rmc-6236-001-05379985","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"RMC-6236-001 examines RMC-6236 safety in advanced solid tumors with specific RAS mutations; discussion of non-small cell lung cancer (NSCLC) combines support for activity beyond G12C with questions about the highlighted response estimate. The report cites 19 physicians, including 15 medical oncologists, and a contributor described in the source as involved in the trial. Further questions concern lower NSCLC dosing and whether previously treated pancreatic ductal adenocarcinoma activity warrants practice change. How can teams explain cohort-specific benefit estimates and toxicity burden while separating evidence from access?","meta_description":"87 sources screened · 196 verified statements (47 from clinicians verified by NPI or staff page) from 50 sources · 9 findings. Updated Nov 4, 2026.","person_names_policy":"role_only","sample_findings":[]},"publication":{"approved_at":"2026-11-04T16:58:25Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":87},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on treatment-history uncertainty in commentary about RAS-targeted therapy for progressive pancreatic cancer.","Not yet captured in this edition: a remark on biomarker-defined combination-trial options and geographic access for patients with non-small cell lung cancer.","Not yet captured in this edition: a view on first-line daraxonrasib plus chemotherapy in RAS-mutant metastatic pancreatic cancer.","Not yet captured in this edition: a view on testing chemotherapy-free treatment against standard care in frontline pancreatic cancer.","Not yet captured in this edition: a view on chemotherapy-free treatment versus standard care in frontline pancreatic cancer.","Not yet captured in this edition: a view on the value of treatment response specifically for patients who respond.","79 passages in 48 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 100 sources about other trials or topics are not included; 398 sources that may describe the trial without naming it were not read.","This report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some potentially relevant sources were not read, and some passages were not fully assessed; unnamed trial references may also have been missed.","Repeated cross-platform posts, reposts, organizational summaries and relayed presentations are not independent HCP votes. The frequency of a view cannot be interpreted as its prevalence in clinical practice.","Some authors' clinical roles are unconfirmed, and video speakers are not identified. Those contributions are described by source rather than assigned inferred credentials or identities.","RMC-6236-001 cohorts, doses, treatment lines and data summaries differ across sources. Historical comparisons and separate phase 3 or combination-study commentary do not establish comparative results for the target study.","Several numerical or textual ambiguities remain, including a 136-versus-137 NSCLC participant count across posts, unclear PDAC outcome denominators in one abbreviated post, inconsistent spoken dose-toxicity figures and an uncertain adverse-event term.","No protocol or exact regulatory label was available. Regulatory, guideline and access statements remain dated commentary rather than a verified current status assessment.","The discussion is concentrated in PDAC and NSCLC. Little can be concluded here about HCP interpretation of CRC, other solid-tumor cohorts or the specific dose-limiting-toxicity endpoint."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":4,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":39,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":49,"context":1},"count":50,"evidence_window":{"end":"2026-09-14","start":"2022-11-11"},"retrieval_snapshot":"2026-11-04T15:18:41.510616Z","timeline":[{"count":1,"week":"2022-W45"},{"count":1,"week":"2023-W15"},{"count":2,"week":"2023-W41"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W33"},{"count":2,"week":"2025-W34"},{"count":3,"week":"2026-W16"},{"count":2,"week":"2026-W17"},{"count":11,"week":"2026-W19"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":16,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05379985:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05379985:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:37590355","quote_policy":"short_quote_link_out"},{"id":"pubmed:38589574","quote_policy":"short_quote_link_out"},{"id":"pubmed:38593348","quote_policy":"short_quote_link_out"},{"id":"pubmed:40056080","quote_policy":"short_quote_link_out"},{"id":"pubmed:42090791","quote_policy":"short_quote_link_out"},{"id":"pubmed:42685317","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-55ap2eggmhhlp5sr4n27nu5u-3lipcykyqdk23","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vwezbhj7wwowu4sbur5npjk-3ml7mzj2fbk22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-m66exquthfrvmkfbxosgeys7-3mntirzpctc2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-onq7arnmwqwb5wctfkgwkyl4-3munezif6z22w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mlaw4vk3bb2n","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7361384799678132225","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7452248046337298433","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501533474324017152","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7501647720995086336","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1647346885936443392:adeee18c-6b46-403d-97e6-cd2760755c66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665068958066565120:bda360f3-851d-4da7-b056-79ce63ff3c6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665069156494897153:7daf40af-b31a-4c77-b8a1-d132bdebdf92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1712845591397433729:d6c4eed4-b08b-4504-ba06-5ea54c09bb27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1712849119176278416:1d1517ed-8ff4-4984-959d-50cf79beb25a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1712923826512687551:57139193-1bd7-422e-ba99-3b8caf720c77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1713180130669973702:e654fab8-ce50-46c2-a1e2-434a7c770560","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715994309848076604:74ed9556-e057-4afc-8b74-c4df243273a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725885818903122284:19dd92b9-c0ec-4689-aa36-48e6941c9e35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1770747059651420256:bbcfcdea-5b37-4b8e-81f3-fad348f88b75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796906216507023857:e0ca45dd-645c-4d04-88f3-ea50c68b6624","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1841861448361824397:595e2036-b9d0-44af-a97b-529fcc69ab3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849033347294511194:a6237d26-5b4a-492a-bafe-6fddd5693d36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1857111756008497196:3ae233cd-deb2-46f5-ab19-80b01824f9d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1878912812027912532:7d26f2a3-aee3-4e74-b5f9-da55eac64a5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1880391653745102914:a0c06ab8-d179-4417-ae5c-cc76d7565bec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1883389332377239732:e66d1f78-d3f9-4fe2-aefd-19f6a89d554b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884262664701923778:74eeda2a-c8ca-46a5-8a05-8e5c41cb1243","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885100680010219791:a6de69a0-889d-4fb1-8892-2ab340ae65f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1907132241555435799:652320d1-c7ec-407b-9791-cc12672f270a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1949394324786991270:24bb18af-b953-4f13-8a30-3d4b1a03b061","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957893631123071164:a60abdf1-7319-4375-bf30-73979e016238","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957895447428887002:05e3a4fe-ad81-412f-8c11-72cb1ba096f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045270812689875449:a47b7906-9256-44bb-ba04-8f94b3471c55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045292904768213086:01406de0-732f-4e81-9435-4cef74bf0ba9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045396104196317393:24e54764-6aba-427a-9083-c2cbdc245ebe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045426214018425244:c77bb3f1-be02-439b-9b17-d81978150b41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045494449375994305:2842de3a-72f5-4f6d-8035-70037b1a9b3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045494993242988633:a3b2e847-b24e-4efb-9b3b-7339a240505f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046198436735922430:35149faf-a8d1-479c-b6bb-f0af0aea79dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046347853149393127:85e5f6e9-43d6-4cc0-a055-f02a44a4c582","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046486679867793635:de868eb3-0fbe-47a8-8fe3-f43dcb919815","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046713600648302595:2a3efc67-2cc6-4a4d-94e0-fa2452ba82fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047692262180814854:48d3d87e-fc6a-4e34-b809-c7d13b43b5ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052133838185185715:1d8bef35-7f41-4549-bbc5-be013198d113","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052136217421152493:4cb467fe-365e-4fa2-8847-e538f59b3ddd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052139766146109598:09d39b5f-b866-4a39-b00c-04b426d8b78d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052176634711560502:0be284e3-ae0b-4866-9883-80ac17e8dd77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052216241218044189:f39cf651-1cdd-4128-8d86-0c2b1aa6968b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052271670065266978:405c2251-14cd-4f96-beed-ffd8422532fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052328852731433271:f610f02c-210d-4c76-8103-72c3b19a15c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052337204802822453:a7933bb6-9982-43dc-90d1-5c6f8d4a4a9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052360374456811901:007590a8-edd2-4ca8-8cfd-78c71b4502ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052944491800039931:f3b9f026-591d-4e23-87b5-d67dfdd4b9e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053302309925380361:4ed8fae2-dcfd-468f-83a1-5361052e9b72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053475143905947781:33b02574-9c83-417c-bf04-c385b54f6966","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055698531743359227:a8b01d54-4edd-4375-9ab1-f5b1fe33d834","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056703437622960508:b8ca4c0f-7f8c-42c6-8867-f6c9eddf3954","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056832780957344229:2ae89cb3-5d5c-489c-91fd-8374ac006ecf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061514236241846475:cc1986c4-02ba-48bf-b16a-0253298cbe6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064223245734199791:51c8fdd3-ef66-4994-a145-409aca931656","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074514869119050118:315b9e1e-8011-4b38-8c78-475016e97f62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094491041684414581:af2330d0-7ce6-40e5-8063-fbf9c0cbd0e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094504463813710317:56f0d65e-e824-4604-a52f-8d0fad76c9f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095260502544863390:5c9b1c6d-de93-4a5e-b839-dc3aff4f3fd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095279644916519007:21d44e37-64e6-4f73-a390-cb7c7aecedcb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095294619084820919:59c8b3c4-5de0-4cd6-a331-da2b8bcc6b9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095295557237719365:3a062f08-bed4-4745-8efd-a5cea8c400c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095318854213771444:b5797a10-6545-4940-981a-2616215efdbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095332187956805753:0b0822dd-3880-44c4-90d6-c0e415d23cd2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095429365190586730:eb2af6ee-83e5-4b78-8467-7e48ecf69cf0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095432616229126398:2152d683-529a-43c4-899f-de84bcb3f00c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095457475046621689:a259efc6-8339-4624-b5bc-b05d37000451","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095558728699269372:76cdc269-5517-4c2d-afcc-a208ad7b1fe8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095606587859591551:2ec60b85-4983-49ac-965c-16ae5c3ad1b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095622050098327660:1fe5dc9f-a8be-4c99-bbd9-c55c9e3c1017","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095785089263116297:bb9f2cd1-f1a2-402b-ae5a-a1a34fb37f27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095881945267802581:6c36b9c4-2e93-4e4a-a2b3-a41ddd0605c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095941885487620349:098e3ab0-de65-40f6-bf35-d25c2df196dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096252812111810945:fbae8545-c7a0-4e01-a09f-d49a12e46890","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099554434347147266:18c06df8-4b67-4fbc-9a3e-8655f33dc7c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102337112368705626:a1abcebc-7e47-4057-acd9-4e1dacbf4d12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102729703018918351:2a5c8e92-54ea-41f7-a65d-d496ca04f5aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103869620394557742:29936c21-2048-453b-b473-f1b8391a088a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107903264297730343:e9742c6c-4f8d-48f4-8d30-718a82f4dcd3","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WSTrTem-e74","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xb3I0EclyRg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yus0-1RdA8s","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":75,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":87},"count":87,"evidence_window":{"end":"2026-10-07","start":"2022-11-11"},"retrieval_snapshot":"2026-11-04T15:18:41.510616Z","timeline":[{"count":1,"week":"2022-W45"},{"count":1,"week":"2023-W15"},{"count":2,"week":"2023-W22"},{"count":4,"week":"2023-W41"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2024-W12"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2024-W43"},{"count":1,"week":"2024-W46"},{"count":2,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":2,"week":"2025-W05"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W14"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W33"},{"count":2,"week":"2025-W34"},{"count":6,"week":"2026-W16"},{"count":6,"week":"2026-W17"},{"count":14,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W21"},{"count":2,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W28"},{"count":21,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: rmc-6236","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"},{"reason":"Unmapped registry condition: Pancreatic Ductal Adenocarcinoma (PDAC)","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RMC-6236-001","aliases":["RMC-6236-001","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS"],"brief_title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"display_condition":"RAS-mutant advanced solid tumors","display_interventions":[["daraxonrasib (RMC-6236)"]],"enrollment":{"count":754,"type":"ESTIMATED"},"interventions":[{"name":"RMC-6236","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05379985","official_title":"A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs","timeFrame":"up to 2.5 years"},{"measure":"Number of Participants with Dose-Limiting Toxicity (DLT)","timeFrame":"21 days"}],"registered_date":{"date":"2022-05-18","type":"ACTUAL"},"registry_last_updated":"2026-05-15","registry_url":"https://clinicaltrials.gov/study/NCT05379985","short_name":"RMC-6236-001","short_name_basis":"canonical_name","sponsor":"Revolution Medicines, Inc.","start_date":{"date":"2022-05-31","type":"ACTUAL"},"study_design":"interventional, na, single group, phase1, phase2","study_ids":[{"id":"RMC-6236-001","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}